Cancer-related Hypercalcemia and Potential Treatments - Volume II

Given the success of the first edition, we are pleased to announce the second volume of the Research Topic “Cancer-related Hypercalcemia and Potential Treatments”. Please find the first edition here.Up to 10% to 30% of cancer patients are affected by hypercalcemia, and cancer-related hypercalcemia is the most common cause of hypercalcemia in hospitalized patients. It is mainly caused by Parathyroid hormone-related protein secretion (PTHrP), osteolytic cytokine production, or excess 1,25-dihydroxy vitamin D production, and is mainly associated with solid tumors. However, hypercalcemia could affect patients with hematologic malignancies as well.A number of clinical features can accompany hypercalcemia, which can be general, gastrointestinal, or neurologic. Untreated severe hypercalcemia can be fatal, and appropriate treatment can ameliorate most of the symptoms and positively affect the quality of life. As treatment and prognosis vary according to the underlying disorder, being able to discriminate the underlying condition causing the abnormal calcium levels is indispensable.In this Research Topic, we aim at collecting Original Research, Review, Mini Review, and Perspective articles on malignant hypercalcemia treatment. Potential themes include, but are not limited to:- Hypercalcemia treatments in cancer patients- New approaches to treat malignant hypercalcemia- Proper diagnosis of malignant hypercalcemia- Molecular and cellular mechanisms involved in malignant hypercalcemia Topic editors: Lorenzo Scappaticcio, Arif Nur Muhammad Ansori, Pierpaolo Trimboli Source: https://www.frontiersin.org/research-topics/76739/cancer-related-hypercalcemia-and-potential-treatments---volume-ii